Get the Stockscreener App
4.76
4.80%
-0.24
After Hours:
4.76
Anavex Life Sciences Corporation stock is traded at $4.76, with a volume of 1.09M.
It is down -4.80% in the last 24 hours and up +24.93% over the past month.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
See More
Previous Close:
$5.00
Open:
$5
24h Volume:
1.09M
Relative Volume:
0.62
Market Cap:
$441.12M
Revenue:
-
Net Income/Loss:
$-48.17M
P/E Ratio:
-8.3509
EPS:
-0.57
Net Cash Flow:
$-37.10M
1W Performance:
+6.73%
1M Performance:
+24.93%
6M Performance:
-49.36%
1Y Performance:
-45.48%
1-Day Range:
$4.695
$5.0199
1-Week Range:
$4.28
$5.1762
52-Week Range:
$2.86
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
4.76 | 463.36M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference - Yahoo Finance
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
What's Going On With Anavex Life Sciences Stock On Wednesday? - Benzinga
Anavex Life Sciences to Present at the Citizens Life Sciences Conference - Anavex Life Sciences
Alzheimer's-focused Anavex CEO to speak at Citizens Life Sciences Conference - Stock Titan
Anavex Life Sciences Corp. (AVXL): Investor Outlook on a Biotechnology Stock with a Potential 393% Upside - DirectorsTalk Interviews
Anavex Adds Veteran Healthcare Leader to Board of Directors - The Globe and Mail
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference - Bitget
Anavex Life Sciences Corp. CEO to Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026 - Quiver Quantitative
Alzheimer’s treatment developer Anavex to speak at TD Cowen health conference - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Below 50-Day Moving AverageHere's What Happened - MarketBeat
EBITDA per share of Anavex Life Sciences Corp. – LSE:0HFR - TradingView
Anavex Life Sciences appoints Dr. Axel Paeger to board By Investing.com - Investing.com India
Anavex Life Sciences appoints Dr. Axel Paeger to board - Investing.com
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors - marketscreener.com
Anavex Life Sciences Corp. (AVXL) Stock Analysis: Unveiling a Remarkable 433.98% Potential Upside - DirectorsTalk Interviews
Why analysts upgrade Anavex Life Sciences Corp. stockAnalyst Upgrade & AI Powered Buy/Sell Recommendations - mfd.ru
Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen - MarketBeat
Anavex Life Sciences Corp. (AVXL): Unlocking a 461% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Q2 EPS Forecast for Anavex Life Sciences Boosted by Analyst - MarketBeat
How cyclical is Anavex Life Sciences Corp.’s revenue stream2025 Earnings Impact & Community Trade Idea Sharing Platform - mfd.ru
Is Anavex Life Sciences Corp. stock undervalued right nowGDP Growth & Stock Market Timing Techniques - mfd.ru
HC Wainwright Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript - Insider Monkey
Breakeven On The Horizon For Anavex Life Sciences Corp. (NASDAQ:AVXL) - Yahoo Finance
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory (NASDAQ:AVXL) - Seeking Alpha
D. Boral Capital Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences reports fiscal 2026 first quarter financial results and provides business update - marketscreener.com
Anavex Life Sciences Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Anavex Life Sciences beats EPS forecast in Q1 2026 - Investing.com India
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot - kare11.com
ANAVEX LIFE SCIENCES ($AVXL) Releases Q1 2026 Earnings - Quiver Quantitative
Anavex Life Sciences : Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update - marketscreener.com
Anavex Life Sciences's Earnings Outlook - Benzinga
Anavex Life Sciences (AVXL) to Release Earnings on Wednesday - MarketBeat
Alzheimer’s drug developer Anavex schedules Feb. 9 results call - Stock Titan
Anavex And Alzheimer's Disease: The Future Never Seems To Be Now - Seeking Alpha
Chipmakers Recap: Does Unity Bancorp Inc meet Warren Buffetts criteriaJuly 2025 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
Anavex Life Sciences (AVXL) Price Target Decreased by 25.00% to 33.66 - MSN
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock - Investing.com
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock By Investing.com - Investing.com Nigeria
Anavex Life Sciences Highlights Oral Alzheimer’s Drug Blarcamesine, Precision Strategy at JPM Conference - MarketBeat
Trading Action: Can Anavex Life Sciences Corp weather a recessionDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Returns Recap: Why Anavex Life Sciences Corp. stock could rally in 2025Market Risk Report & Momentum Based Trading Ideas - Bộ Nội Vụ
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease - Anavex Life Sciences
Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Support Innovative Alzheimer's Disease Treatments in Europe - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - Eastern Progress
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm - Eastern Progress
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anavex Life Sciences Corporation Stock (AVXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):